[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.22. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
April 18, 2019

Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma

Author Affiliations
  • 1Vanderbilt University School of Medicine, Nashville, Tennessee
  • 2Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee
  • 3Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
  • 4Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
JAMA Oncol. 2019;5(6):906-908. doi:10.1001/jamaoncol.2019.0046

Immune checkpoint inhibitors block key mediators of immune tolerance, producing antitumor responses and autoimmunelike toxic effects.1 Toxic effects indicate immune activation against host tissues, although it remains controversial whether this off-target activity indicates concurrent antitumor immunity.2-4 Herein, we retrospectively studied whether cutaneous toxic effects correlated with outcomes in patients with advanced melanoma treated with immune checkpoint inhibitors.

We reviewed electronic medical records of patients treated with anti–programmed cell death 1 (anti–PD-1) with or without ipilimumab from a single center. We assessed demographics, cutaneous toxic effects, steroid administration, and outcomes by retrospective review. The Vanderbilt University Medical Center institutional review board approved the study, with a waiver of patient consent.

×